314 related articles for article (PubMed ID: 10215558)
1. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation.
Catherwood E; Fitzpatrick WD; Greenberg ML; Holzberger PT; Malenka DJ; Gerling BR; Birkmeyer JD
Ann Intern Med; 1999 Apr; 130(8):625-36. PubMed ID: 10215558
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation.
Eckman MH; Falk RH; Pauker SG
Arch Intern Med; 1998 Aug 10-24; 158(15):1669-77. PubMed ID: 9701102
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation.
Seto TB; Taira DA; Tsevat J; Manning WJ
J Am Coll Cardiol; 1997 Jan; 29(1):122-30. PubMed ID: 8996304
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation.
Gage BF; Cardinalli AB; Albers GW; Owens DK
JAMA; 1995 Dec; 274(23):1839-45. PubMed ID: 7500532
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic strategies for atrial fibrillation. The value of decision analysis.
Greenberg ML; Malenka DJ; Disch DL
Cardiol Clin; 1996 Nov; 14(4):623-40. PubMed ID: 8950062
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
[TBL] [Abstract][Full Text] [Related]
8. Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone.
Disch DL; Greenberg ML; Holzberger PT; Malenka DJ; Birkmeyer JD
Ann Intern Med; 1994 Mar; 120(6):449-57. PubMed ID: 8311367
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation.
Gage BF; Cardinalli AB; Owens DK
Stroke; 1998 Jun; 29(6):1083-91. PubMed ID: 9626276
[TBL] [Abstract][Full Text] [Related]
10. Treatment of nonvalvular atrial fibrillation.
Stettin GD
West J Med; 1995 Apr; 162(4):331-9. PubMed ID: 7747499
[TBL] [Abstract][Full Text] [Related]
11. Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation.
Man-Son-Hing M; Laupacis A
Arch Intern Med; 2002 Mar; 162(5):541-50. PubMed ID: 11871922
[TBL] [Abstract][Full Text] [Related]
12. Atrial fibrillation: rate control often better than rhythm control.
Prescrire Int; 2004 Apr; 13(70):64-9. PubMed ID: 15148984
[TBL] [Abstract][Full Text] [Related]
13. Comparison of rate control versus rhythm control for management of atrial fibrillation in patients with coexisting heart failure: a cost-effectiveness analysis.
Perez A; Touchette DR; DiDomenico RJ; Stamos TD; Walton SM
Pharmacotherapy; 2011 Jun; 31(6):552-65. PubMed ID: 21923439
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.
Lee VW; Tsai RB; Chow IH; Yan BP; Kaya MG; Park JW; Lam YY
BMC Cardiovasc Disord; 2016 Aug; 16(1):167. PubMed ID: 27581874
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation.
de Paola AA; Figueiredo E; Sesso R; Veloso HH; Nascimento LO;
Int J Cardiol; 2003 Apr; 88(2-3):157-66. PubMed ID: 12714194
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.
Eckman MH; Rosand J; Greenberg SM; Gage BF
Ann Intern Med; 2009 Jan; 150(2):73-83. PubMed ID: 19153410
[TBL] [Abstract][Full Text] [Related]
18. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
O'Brien CL; Gage BF
JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
[TBL] [Abstract][Full Text] [Related]
19. Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis.
Middlekauff HR; Stevenson WG; Gornbein JA
Arch Intern Med; 1995 May; 155(9):913-20. PubMed ID: 7726699
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Kamel H; Johnston SC; Easton JD; Kim AS
Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
